See more : Jumbo Bag Limited (JUMBO.BO) Income Statement Analysis – Financial Results
Complete financial analysis of Kiromic BioPharma, Inc. (KRBP) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Kiromic BioPharma, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- CAQ Holdings Limited (CAQ.AX) Income Statement Analysis – Financial Results
- Focus Energia Holding Participações S.A. (POWE3.SA) Income Statement Analysis – Financial Results
- Energoinstal S.A. (ENI.WA) Income Statement Analysis – Financial Results
- Recharge Acquisition Corp. (RCHG) Income Statement Analysis – Financial Results
- Southwestern Medical Solutions, Inc. (SWNM) Income Statement Analysis – Financial Results
Kiromic BioPharma, Inc. (KRBP)
About Kiromic BioPharma, Inc.
Kiromic BioPharma, Inc., an artificial intelligence driven allogeneic cell therapy company, engages in developing the multi-indication allogeneic T cell therapies that exploits the natural potency of the Gamma Delta T cell to target solid tumors. The company develops ALEXIS-ISO-1, an allogenic gamma delta CAR-T cell therapy product candidate targeting Isomesothelin; and ALEXIS-PRO-1, an allogeneic gamma delta chimeric T cell therapy product candidate targeting PD-L1. It has license agreements with CGA 369 Intellectual Holdings, Inc. and Longwood University, as well as a research and development collaboration agreement with Molipharma, S.R.L. The company also has strategic alliance agreement with Leon Office (H.K.) Ltd. The company was formerly known as Kiromic, Inc. and changed its name to Kiromic BioPharma, Inc. in December 2019. Kiromic BioPharma, Inc. was founded in 2006 and is headquartered in Houston, Texas.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 2.80M | 2.07M | 469.80K | 200.00K | 87.50K | 80.90K |
| Gross Profit | -2.80M | -2.07M | -469.80K | -200.00K | -87.50K | -80.90K |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 9.62M | 13.92M | 11.37M | 5.05M | 1.20M | 1.42M |
| General & Administrative | 10.31M | 17.19M | 13.94M | 14.14M | 2.50M | 1.76M |
| Selling & Marketing | -2.80M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 7.52M | 17.19M | 13.94M | 14.14M | 2.50M | 1.76M |
| Other Expenses | 0.00 | 0.00 | 53.40K | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 17.14M | 31.11M | 25.31M | 19.20M | 3.71M | 3.18M |
| Cost & Expenses | 19.94M | 31.11M | 25.31M | 19.20M | 3.71M | 3.18M |
| Interest Income | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | -1.85M | 166.50K | 12.20K | 3.30K | 22.50K | 633.10K |
| Depreciation & Amortization | 2.80M | 2.07M | 469.80K | 200.00K | 87.50K | 80.90K |
| EBITDA | -16.30M | -32.50M | -25.74M | -19.00M | -3.62M | -3.10M |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -19.94M | -31.11M | -25.74M | -19.20M | -3.71M | -3.18M |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | -1.01M | -3.62M | 147.00K | -3.30K | -22.50K | -633.10K |
| Income Before Tax | -20.95M | -34.73M | -25.59M | -19.20M | -3.73M | -3.82M |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 0.00 | 3.45M | 65.60K | 3.30K | 22.50K | -80.24K |
| Net Income | -21.29M | -38.18M | -25.65M | -19.20M | -3.75M | -3.82M |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -21.41 | -70.12 | -67.40 | -79.08 | -29.00 | -32.40 |
| EPS Diluted | -21.41 | -70.12 | -67.40 | -79.08 | -29.00 | -32.40 |
| Weighted Avg Shares Out | 1.10M | 544.53K | 380.61K | 242.83K | 129.32K | 117.76K |
| Weighted Avg Shares Out (Dil) | 1.10M | 544.53K | 380.61K | 242.83K | 129.32K | 117.76K |
Kiromic BioPharma Announces Settlement of Previously Disclosed SEC Investigation
HOUSTON--(BUSINESS WIRE)---- $KRBP--Kiromic BioPharma, Inc. (OTCQB: KRBP) (“Kiromic” or the “Company”) today announced that it has entered into a settlement agreement with the U.S. Securities and Exchange Commission (the “SEC”), resolving the previously disclosed SEC investigation arising from the non-disclosure...
SEC Charges Kiromic BioPharma and Two Former C-Suite Executives with Misleading Investors about Status of FDA Reviews
Washington, D.C.--(Newsfile Corp. - December 3, 2024) - The Securities and Exchange Commission today filed settled charges against Houston-based biotherapeutics company Kiromic BioPharma, Inc., its former CEO, Maurizio Chiriva-Internati, and its former chief financial officer, Tony Tontat, for failing to...
Kiromic BioPharma Reports Favorable Ongoing Clinical Results From Fourth and Sixth Patients Enrolled in Deltacel-01
HOUSTON--(BUSINESS WIRE)--Kiromic BioPharma, Inc. (OTCQB: KRBP) (“Kiromic” or the “Company”) reports favorable ongoing efficacy results from follow-up visits for Patient 4 and Patient 6 in its Deltacel-01 Phase 1 clinical trial. This trial is evaluating Deltacel™ (KB-GDT-01), the Company's allogeneic,...
Kiromic BioPharma Activates the University of Arizona Cancer Center as the Fifth Clinical Trial Site in the Ongoing Phase 1 Deltacel-01 Trial
HOUSTON--(BUSINESS WIRE)--Kiromic BioPharma, Inc. (OTCQB: KRBP) (“Kiromic” or the “Company”) announces that the University of Arizona Cancer Center (UACC) has been activated as the fifth clinical trial site in the Deltacel-01 Phase 1 trial evaluating Deltacel™ (KB-GDT-01), Kiromic's allogeneic, off-the-shelf,...
Kiromic BioPharma Provides Update on Part 1 of the Deltacel-01 Trial
HOUSTON--(BUSINESS WIRE)--Kiromic BioPharma, Inc. (OTCQB: KRBP) (“Kiromic” or the “Company”) reports interim results near the completion of Part 1 of its Deltacel-01 Phase 1 clinical trial. This trial is evaluating Deltacel™ (KB-GDT-01), the Company's allogeneic, off-the-shelf, Gamma Delta T-cell (GDT)...
Kiromic BioPharma Provides Updates on its Deltacel-01 Clinical Trial
HOUSTON--(BUSINESS WIRE)--Kiromic BioPharma, Inc. (OTCQB: KRBP) (“Kiromic” or the “Company”) reports follow-up results from the second, third and fourth patients enrolled in its Deltacel-01 Phase 1 clinical trial. This trial is evaluating Deltacel™ (KB-GDT-01), the Company's allogeneic, off-the-shelf, Gamma Delta...
Kiromic BioPharma Reports Six-Month Results from First Patient Enrolled in Deltacel-01 Clinical Trial
HOUSTON--(BUSINESS WIRE)--Kiromic BioPharma, Inc. (OTCQB: KRBP) (“Kiromic” or the “Company”) reports favorable six-month follow-up results from the first patient enrolled in the Deltacel-01 Phase 1 clinical trial. This trial is evaluating Deltacel™ (KB-GDT-01), the Company's allogeneic, off-the-shelf, Gamma Delta T-cell...
Kiromic BioPharma Reports Favorable Results at Six Weeks from Fourth Patient in Deltacel-01 Clinical Trial
HOUSTON--(BUSINESS WIRE)--Kiromic BioPharma, Inc. (OTCQB: KRBP) (“Kiromic” or the “Company”) reports favorable safety and tolerability, and early efficacy in the fourth patient enrolled in the Company's Deltacel-01 Phase 1 clinical trial. Deltacel-01 is evaluating Deltacel™ (KB-GDT-01), Kiromic's allogeneic, off-the-shelf, Gamma...
Kiromic BioPharma Adds UPMC as Fourth Deltacel-01 Clinical Trial Site
HOUSTON--(BUSINESS WIRE)--Kiromic BioPharma, Inc. (OTCQB: KRBP) (“Kiromic” or the “Company”) announces that UPMC in Pittsburgh, Pennsylvania has been activated as the fourth clinical trial site in the Deltacel-01 Phase 1 trial evaluating Deltacel™ (KB-GDT-01), Kiromic's allogeneic, off-the-shelf, Gamma Delta T-cell...
Kiromic BioPharma Reports Consistent Favorable Safety, Tolerability, and Efficacy in Deltacel-01 Clinical Trial First Three Patients
HOUSTON--(BUSINESS WIRE)---- $KRBP #GDT--Kiromic BioPharma Reports Consistent Favorable Safety, Tolerability, and Efficacy in Deltacel-01 Clinical Trial First Three Patients.
Source: https://incomestatements.info
Category: Stock Reports